2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Detection of retinal and blood Aβ oligomers with nanobodies

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Abnormal retinal changes are increasingly recognized as an early pathological change in Alzheimer's disease (AD). Although amyloid beta oligomers (Aβo) have been shown to accumulate in the blood and retina of AD patients and animals, it is not known whether the early Aβo deposition precedes their accumulation in brain.

          Methods and results

          Using nanobodies targeting Aβ 1‐40 and Aβ 1‐42 oligomers we were able to detect Aβ oligomers in the retina and blood but not in the brain of 3‐month‐old APP/PS1 mice. Furthermore, Aβ plaques were detected in the brain but not the retina of 3‐month‐old APP/PS1 mice.

          Conclusion

          These results suggest that retinal accumulation of Aβo originates from peripheral blood and precedes cognitive decline and Aβo deposition in the brain. This provides a very strong basis to develop and implement an “eye test” for early detection of AD using nanobodies targeting retinal Aβ.

          Related collections

          Most cited references57

          • Record: found
          • Abstract: found
          • Article: not found

          High performance plasma amyloid-β biomarkers for Alzheimer’s disease

          To facilitate clinical trials of disease-modifying therapies for Alzheimer's disease, which are expected to be most efficacious at the earliest and mildest stages of the disease, supportive biomarker information is necessary. The only validated methods for identifying amyloid-β deposition in the brain-the earliest pathological signature of Alzheimer's disease-are amyloid-β positron-emission tomography (PET) imaging or measurement of amyloid-β in cerebrospinal fluid. Therefore, a minimally invasive, cost-effective blood-based biomarker is desirable. Despite much effort, to our knowledge, no study has validated the clinical utility of blood-based amyloid-β markers. Here we demonstrate the measurement of high-performance plasma amyloid-β biomarkers by immunoprecipitation coupled with mass spectrometry. The ability of amyloid-β precursor protein (APP)669-711/amyloid-β (Aβ)1-42 and Aβ1-40/Aβ1-42 ratios, and their composites, to predict individual brain amyloid-β-positive or -negative status was determined by amyloid-β-PET imaging and tested using two independent data sets: a discovery data set (Japan, n = 121) and a validation data set (Australia, n = 252 including 111 individuals diagnosed using 11C-labelled Pittsburgh compound-B (PIB)-PET and 141 using other ligands). Both data sets included cognitively normal individuals, individuals with mild cognitive impairment and individuals with Alzheimer's disease. All test biomarkers showed high performance when predicting brain amyloid-β burden. In particular, the composite biomarker showed very high areas under the receiver operating characteristic curves (AUCs) in both data sets (discovery, 96.7%, n = 121 and validation, 94.1%, n = 111) with an accuracy approximately equal to 90% when using PIB-PET as a standard of truth. Furthermore, test biomarkers were correlated with amyloid-β-PET burden and levels of Aβ1-42 in cerebrospinal fluid. These results demonstrate the potential clinical utility of plasma biomarkers in predicting brain amyloid-β burden at an individual level. These plasma biomarkers also have cost-benefit and scalability advantages over current techniques, potentially enabling broader clinical access and efficient population screening.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide.

            The distinct protein aggregates that are found in Alzheimer's, Parkinson's, Huntington's and prion diseases seem to cause these disorders. Small intermediates - soluble oligomers - in the aggregation process can confer synaptic dysfunction, whereas large, insoluble deposits might function as reservoirs of the bioactive oligomers. These emerging concepts are exemplified by Alzheimer's disease, in which amyloid beta-protein oligomers adversely affect synaptic structure and plasticity. Findings in other neurodegenerative diseases indicate that a broadly similar process of neuronal dysfunction is induced by diffusible oligomers of misfolded proteins.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

              We examined whether plasma β-amyloid (Aβ)42/Aβ40, as measured by a high-precision assay, accurately diagnosed brain amyloidosis using amyloid PET or CSF p-tau181/Aβ42 as reference standards.
                Bookmark

                Author and article information

                Contributors
                m.tayebi@westernsydney.edu.au
                Journal
                Alzheimers Dement (Amst)
                Alzheimers Dement (Amst)
                10.1002/(ISSN)2352-8729
                DAD2
                Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring
                John Wiley and Sons Inc. (Hoboken )
                2352-8729
                06 May 2021
                2021
                : 13
                : 1 ( doiID: 10.1002/dad2.v13.1 )
                : e12193
                Affiliations
                [ 1 ] School of Medicine Western Sydney University Campbelltown New South Wales Australia
                [ 2 ] South Western Sydney Clinical School, Faculty of Medicine UNSW, Liverpool Hospital Liverpool New South Wales Australia
                [ 3 ] Ingham Institute of Applied Medical Research Liverpool New South Wales Australia
                [ 4 ] Department of Optometry and Vision Sciences University of Melbourne Melbourne Victoria Australia
                [ 5 ] Department of Neurosurgery Maxine Dunitz Neurosurgical Research Institute and Department of Biomedical Sciences Cedars‐Sinai Medical Center Los Angeles California USA
                Author notes
                [*] [* ] Correspondence

                Mourad Tayebi, Biomedical Sciences, School of Medicine, Western Sydney University, Campbelltown, Sydney, NSW 2560, Australia.

                E‐mail: m.tayebi@ 123456westernsydney.edu.au

                Author information
                https://orcid.org/0000-0001-8664-6918
                Article
                DAD212193
                10.1002/dad2.12193
                8101010
                33977118
                09196590-8e0b-4a4c-91a8-cfcc45078845
                © 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 13 April 2021
                : 06 January 2021
                : 13 April 2021
                Page count
                Figures: 7, Tables: 3, Pages: 12, Words: 7039
                Funding
                Funded by: Ainsworth Medical Research Innovation Fund
                Categories
                Research Article
                Retinal Imaging
                Custom metadata
                2.0
                2021
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.2 mode:remove_FC converted:06.05.2021

                amyloid beta oligomers,alzheimer's disease,app/ps1 mice,blood immunodetection,early alzheimer's disease diagnosis,nanobodies,retinal immunodetection

                Comments

                Comment on this article